Authors: Ouellet, D Periclou, AP Johnson, RD Woodworth, JR Lalonde, RL

Citation: D. Ouellet et al., Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer, CANC CHEMOT, 46(3), 2000, pp. 227-234

Authors: Olson, SC Bockbrader, H Boyd, RA Cook, J Koup, JR Lalonde, RL Siedlik, PH Powell, JR

Citation: Sc. Olson et al., Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process - Experience at Parke-Davis, CLIN PHARMA, 38(5), 2000, pp. 449-459

Authors: Geoffroy, P Lalonde, RL Ahrens, R Clarke, W Hill, MR Vaughan, LM Grossman, J

Citation: P. Geoffroy et al., Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros (R)) and albuterol by MDI in patients with asthma, ANN ALLER A, 82(4), 1999, pp. 377-382

Authors: Gaudreault, J Lalonde, RL

Citation: J. Gaudreault et Rl. Lalonde, Truncated area under the curve as a measure of relative extent of bioavailability: Evaluation using experimental data and Monte Carlo simulations - The authors reply, PHARM RES, 16(7), 1999, pp. 1145-1146

Authors: Lalonde, RL Ouellet, D Kimanani, EK Potvin, D Vaughan, LM Hill, MR

Citation: Rl. Lalonde et al., Comparison of different methods to evaluate population dose-response and relative potency: Importance of interoccasion variability, J PHAR BIOP, 27(1), 1999, pp. 67-83

Authors: Lalonde, RL Gaudreault, J Karhu, DA Marriott, TB

Citation: Rl. Lalonde et al., Mixed-effects modeling of the pharmacodynamic response to the calcimimeticagent R-568, CLIN PHARM, 65(1), 1999, pp. 40-49